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Abstract 
To evaluate the safety and outcome of embolization as treatment for persistent type 2 endoleak (T2EL) occurring after 
abdominal aortic stent graft implantation. This retrospective study included seven consecutive patients (one female, 
six males, mean age 72 years, range 66–88 years) with T2EL between January 2011 and September 2012. In all, T2EL 
was associated with an increase more than 5 mm in the aneurysm. The endoleak cavity or feeding artery was embo-
lized with coils and/or n-butyl cyanoacrylate. Clinical success was defined as regression or stabilization of the aneu-
rysm sac irrespective of residual endoleaks on follow-up CT studies. At the time of T2EL intervention, mean aneurysm 
sac diameter was 63 mm (range 52–72 mm), and mean increase size of aneurysm sac diameter was 7 mm (range 
5–13). Mean follow-up period was 6.0 ± 6.2 months (range 3–18 months). Our technical success rate was 100 %. 
Clinical success was obtained in 5 (71.4 %) of the seven patients. One patient was embolized three times due to sac 
expansion. T2EL was treated by transarterial embolization in eight procedures, and one procedure was performed by 
direct puncture embolization. There were no major complications; two procedures elicited minor complications: tran-
sient back pain and muscle weakness of the left lower leg. We suggest embolization was safe and effective treatment, 
a less invasive treatment option comparison to open repair, as one choice to address T2EL.
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Background
Over the last several years, endovascular aneurysm repair 
(EVAR) has become an effective alternative to open sur-
gery for abdominal aortic aneurysms (AAA). Endoleaks 
are known as the most common complications of EVAR 
and are classified into four types according to cause. Type 
1 endoleak is caused by antegrade flow into the aneu-
rysm sac, which may occur at the attachment site. Type 
2 endoleak (T2EL) is retrograde flow in the collateral 
side-branch arteries, type 3 endoleak is antegrade flow 
at the junction point between graft components, and 
type 4 endoleak is caused graft wall porosity (Rhee et al. 
2003; Haulon et al. 2001; Faries et al. 2003; Axelrod et al. 
2004). T2EL is the most frequently occurring endoleak 
and occurs in approximately 10–25  % of patients who 
undergo EVAR (Rhee et al. 2003; Baum et al. 2002; Stav-
ropoulos et al. 2005). Blood enters the aneurysm through 
a circuitous route, emptying into the aneurysm sac via 
retrograde flow. This flow is usually through one or more 
lumbar arteries or the inferior mesenteric artery (Rhee 
et al. 2003; Baum et al. 2002; Mansueto et al. 2005).
There is widespread agreement that type 1 and type 3 
endoleaks require urgent treatment (Rhee et  al. 2003), 
but no such consensus exists at this time regarding treat-
ment of T2ELs. In fact, persistent T2ELs would often 
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decrease or disappear without therapy (Funaki et al. 2012; 
Nevala et  al. 2010). However, they are sometimes asso-
ciated with expansion and rupture of the aneurysm sac, 
then a treatment is required. Treatment options for T2EL 
include transarterial embolization (TAE), embolization 
after direct puncture (DP) by the abdominal or translum-
bar approach, transcaval embolization, and open surgical 
repair (Baum et al. 2002; Stavropoulos et al. 2005; Man-
sueto et al. 2005; Nevala et al. 2010; Ellis et al. 2003). The 
embolic materials used in embolization have been coils, 
n-butyl-2-cyanoacrylate (NBCA) (Histoacryl; B-Braun, 
Germany), thrombin, ethylene vinyl alcohol copolymer, 
and gelfoam (Baum et al. 2002; Stavropoulos et al. 2005; 
Nevala et al. 2010; Ellis et al. 2003; Khaja et al. 2014).
The purpose of the present study was to evaluate the 




Written informed consent was obtained from all patients. 
Between January 2011 and September 2012, seven con-
secutive patients (six men and one woman, mean age 
72 years, range 66–88 years) underwent nine sessions of 
embolization for T2EL at affiliated hospitals. All institu-
tions do not require institutional review board approval 
for this type of clinical observational study, and our study 
carried out according to all affiliated hospitals guidelines. 
In all patients, T2EL was detected on follow-up com-
puted tomography (CT) scans and an increase in the size 
of the aneurysm was proven. Sac size was measured at the 
largest minor axis diameter on the axial image. Indication 
for treatment of T2EL was defined as an increase in the 
aneurysm >5  mm in diameter compared with CT find-
ings performed immediately after the EVAR procedure 
regardless of the length of the T2EL. Clinical symptoms 
were not present in any patient. Candidates for embo-
lization were selected by consensus between interven-
tional radiologists and cardiovascular surgeons at a case 
presentation conference. At the time of the T2EL inter-
ventions, the mean aneurysm sac diameter was 63  mm 
(range 52–72 mm) and mean increase in the diameter of 
the aneurysm sac was 7 mm (range 5–13 mm). Average 
time between primary EVAR and the procedure to treat 
T2EL was 20 months (range 13–50 months). The types of 
endograft used were the Zenith (Cook, Bloomington, IN, 
USA) in four patients and the EXCLUDER (Gore, Flag-
staff, AZ, USA) in three patients.
The embolization technique involved entering the 
endoleak cavity and/or feeding artery with a mixture of 
NBCA and lipiodol and/or coils by TAE or DP. To per-
form TAE, the common femoral artery was punctured 
and a 4-F catheter was inserted. Then a microcatheter 
was coaxially advanced. Catheterized arteries were the 
ascending lumbar arteries into which the catheter was 
advanced via the hypogastric artery or the inferior mes-
enteric artery into which the catheter was advanced 
via the superior mesenteric artery through the middle 
ascending left colic arcade or arc of Riolan. If possible, 
the microcather was further advanced to the portion of 
the endoleak within the aneurysm sac. After an arterio-
gram from the microcatheter was obtained to decide the 
point from which embolic agents were inserted, embo-
lization was performed (Fig.  1e). As embolic agents, 
microcoils and/or NBCA were used. NBCA was used 
only in patients in whom the sac could be catheterized. 
The ratio of NBCA to lipiodol was 1:2–10. In patients in 
whom the sac could not be catheterized (n = 3), the feed-
ing artery was embolized with microcoils as closely as 
possible to the sac.
To perform DP embolization (Fig. 2b), while the patient 
was in the prone position, the endoleak cavity was punc-
tured with an 18-gauge needle under fluoroscopic guid-
ance. After confirming that blood was aspirated, the 
0.035-in. guide wire included in the commercially avail-
able kit was advanced into the leak, followed by advance-
ment of a 4-F sheath. Subsequently, the patient was 
moved from the angiography room to the CT room, in 
which CT was performed to confirm that the tip of the 
sheath was correctly located. After the patient returned 
to the angiography room, a 4-F catheter and microcath-
eter were inserted into the endoleak cavity. NBCA and 
coils were used in an attempt to fill the aneurysm sac. 
The ratio of NBCA to lipiodol was 1:3.
The standard post-embolization surveillance proto-
col included CT angiography at 3, 6, and 12 months and 
semi-annually thereafter.
The following parameters were retrospectively inves-
tigated: (1) technical success, (2) clinical success, (3) 
complications, and (4) effectiveness of the treatment. 
Technical success was defined as occlusion of the 
endoleak sac or feeding artery confirmed by angiography 
performed immediately after TAE. With DP, technical 
success was defined as confirmation by CT performed 
immediately after embolization that the endoleak was 
filled with NBCA. Clinical success was defined as regres-
sion or stabilization of the aneurysm sac (i.e. shrinkage or 
no further growth) irrespective of the existence of resid-
ual endoleaks during continued follow-up (minimum 
3  months follow-up). Procedural and post-procedural 
complications were recorded according to the Society of 
Interventional Radiology clinical practice guidelines.
Results
Overall, nine procedures (eight TAE, 1 DP) were per-
formed for seven patients (Table 1). Embolic agents used 
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Fig. 1 Images of an 88-year-old man with T2EL (case no 1, Table 1). a Enhanced CT showed that the aneurysm expanded with persistence of T2EL 
(arrow) 15 months after EVAR. b Endoleak angiogram performed via a microcatheter demonstrated that the endoleak involved four vessels (arrows). 
Arrowhead indicates the micro catheter tip that was advanced into the endoleak sac through the left fourth lumbar artery. c Roentgenogram 
showed NBCA injected to fill simultaneously the aneurysmal sac (arrowheads) and the involved lumbar arteries (arrows). d Plain CT showed radio-
paque NBCA accumulations in the endoleak sac (arrow) and lumbar arteries (arrowheads). e Enhanced CT obtained 6 months after the embolization 
showed another small endoleak (arrow) with no further expansion of the aneurysm
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were microcoils (n  =  6) and NBCA (n  =  5). Technical 
success was achieved in all nine procedures. Clinical suc-
cess was achieved in five of the seven patients irrespective 
of technical success. The mean follow-up period for the 
seven patients was 6 ± 6.2 months (range 3–18 months). 
There was no instance of aneurysm rupture or aneurysm-
related mortality.
Residual endoleak was recognized in five patients 
after the first procedure, with the size of the aneurysm 
sac being unchanged in four patients but increasing in 
the remaining patient. In that patient, two additional 
interventions were performed. However, although the 
endoleak was resolved after the third intervention, 
enlargement of the aneurysm could not be stopped. 
Currently the patient cannot receive further treatment 
because of severe heart failure.
The T2EL disappeared in two of the seven patients 
after the first embolization. However, an increase 
in the aneurysm sac was recognized in one of these 
two patients. In this patient the aneurysm was stable 
6 months later, but had increased 5 mm a year after that. 
The residual endoleak was not visualized on CT angiog-
raphy. For this patient superior mesenteric and internal 
iliac angiography was performed, but the endoleak could 
not be visualized. Because of the continued sac expansion 
without the presence of endoleak on angiography and CT 
angiography, this patient is presently being meticulously 
observed.
There were two minor procedure-related complica-
tions. Two patients experienced back pain, one of which 
developed transient slight muscle weakness of the left 
lower leg. Both complications were self-limiting and 
resolved without therapy.
Discussion
T2EL is the most common complication of EVAR. Pre-
viously reported series of T2EL embolization included 
patients with not only enlarging but also stable aneu-
rysms (Baum et al. 2002; Stavropoulos et al. 2005, 2009; 
Nevala et  al. 2010; Kasirajan et  al. 2003). Explanation 
of the necessity of embolization of a stable aneurysm is 
based on the existence of near-systemic pressure in the 
aneurysm sac of patients with T2ELs (Rhee et al. 2003). 
However, many physicians have the different opinion 
that treatment for T2ELs is required only when the aneu-
rysm is expanding (Faries et al. 2003; Funaki et al. 2012; 
Table 1 Demographics and results in patients who underwent endoleak embolization
TAE transarterial embolization, DP embolization after direct puncture, NBCA n-butyl-2-cyanoacrylate

























Yes + No change
2 66/M 57 TAE Endoleak sac NBCA (1:10)a Yes Back pain Yes − No change
3 83/M 72 TAE Endoleak sac NBCA (1:10)a Yes − Yes + No change
4 72/M 60 TAE Main feeder Coil Yes − Yes + No change
5 66/F 52 TAE Endoleak sac Coil + NBCA 
(1:2)a
Yes − Yes + No change
6 87/M ➀ 72 TAE Main feeder Coil Yes − No + Increase
➁ 75 TAE Main feeder Coil Yes − + Increase
 ➂ 80 DP Endoleak sac Coil + NBCA 
(1:3)a
Yes − − Increase
7 72/M 63 TAE Main feeder Coil Yes − No − Increase
(See figure on previous page.) 
Fig. 2 Images of an 87-year-old man with T2EL (case no. 6, Table 1). a Angiography in the prone position showed no endoleak before the third 
embolization. Lumbar artery and middle sacral artery were filled with coils (arrow) as a result of previous TAE. b Plain CT showed that the tip of the 
sheath that had been advanced after direct puncture under fluoroscopic guidance was correctly located. c Roentgenogram obtained after the third 
embolization showed NBCA and coils (arrow) in the endoleak sac. d Enhanced CT obtained 5 days after the third embolization showed NBCA and 
contrast media in the endoleak sac. Diameter of the aneurysm was 80 mm. e Enhanced CT obtained 6 months after the third embolization showed 
no endoleak; however, growth of the aneurysm sac was confirmed. Diameter of the aneurysm was 83 mm
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Ellis et al. 2003; Steinmetz et al. 2004; Gunasekaran et al. 
2013). Many T2ELs will resolve spontaneously and many 
others that persist do not lead to adverse outcomes. 
Furthermore, Gallagher et  al. (2012) reported that per-
sistent T2ELs without sac expansion were not at risk 
of rupture. We believe that treating a T2EL without sac 
expansion has little clinical significance. Hence, we per-
formed embolization of a T2EL for only cases in which 
sac enlargement was confirmed.
In the present study, clinical success was achieved in 
five of the seven patients. In one of the two patients expe-
riencing clinical failure, the T2EL disappeared after the 
third intervention; however, we could not stop enlarge-
ment of the aneurysm. In both of these patients with sac 
expansion even after the final treatment for T2EL, the 
T2EL was no longer evident on CT angiography, and in 
one disappearance of the T2EL was also confirmed by 
angiography. There are two possible reasons for continu-
ous enlargement of the aneurysm. First, T2ELs that are 
invisible by both angiography and CT angiography exist. 
Second, there are causes of enlargement of aneurysms 
other than T2EL. Aziz et al. (2012) reported that percu-
taneous endovascular intervention for a T2EL with aneu-
rysm sac growth does not alter the rate of aneurysm sac 
growth. They reported that in 42 patients who underwent 
a T2EL intervention the mean diameters of the aneurysm 
were 6.1 ±  1.6  cm at EVAR, 6.6 ±  1.5  cm at the initial 
T2EL treatment, and 6.9 cm ± 1.7 cm at the last follow-
up. There were no significant differences in sac growth 
pre- and post-T2EL treatment (Aziz et al. 2012). Indeed, 
there were cases in which the increase in the aneurysm 
was not arrested after T2EL treatment. On the other 
hand, in many cases the enlargement was arrested by per-
cutaneous endovascular intervention. Funaki et al. (2012) 
reported treatment of a T2EL in 16 patients with grow-
ing aneurysms, with technical success observed in 88 % 
(14 of 16 patients) and clinical success achieved in 100 % 
(16 or 16 patients). Furthermore, with regard to the clini-
cal success rate of treatment of a T2EL with an enlarg-
ing aneurysm, Gallagher et  al. (2012) reported a rate of 
75.9  % (22 of 29 patients) and Steinmentz et  al. (2004) 
reported a rate of 100 % (five of five patients). Hence, we 
believe that it is worth trying embolization initially and 
surgical therapy is necessary if embolization fails and the 
increase of aneurysms continues.
Sac embolization and branch vessel embolization have 
been the most frequently used procedures for T2EL treat-
ment. Baum et al. (2002) in a comparison of embolization 
after DP with TAE of only a single feeding artery observed 
a residual T2EL in 80 % of the TAE group but in only 8 % of 
the DP group. However, they did not describe the outcome 
of sac expansion after embolization. In the present study 
sac embolization was not achieved in any case. In a patient 
for whom branch vessel embolization was performed, 
aneurysm growth was arrested (case no. 4, Table 1). On the 
other hand, in a patient for whom sac embolization was 
performed, aneurysm growth was not arrested (case no. 
6, Table 1). Among five patients with no further growth in 
the aneurysm, T2EL persisted in four patients at follow-up 
CT angiography. We believe that in a patient with a grow-
ing aneurysm arresting growth and preventing rupture 
are the best indicators of clinical success, not the presence 
or absence of an endoleak as shown on CT. Funaki et al. 
(2012) noted that persistent endoleak was observed after 
embolization in two patients in whom there was technical 
failure. But the aneurysm growth was arrested and both 
patients had maintained stable aneurysms at their follow-
up. From this, we believe that decreasing perfusion to 
the sac may stabilize growing aneurysms in patients with 
T2EL and the inability to completely eradicate a small 
endoleak does not necessarily equate clinical failure.
There were two complications in this series: back pain 
and muscle weakness of the left lower leg caused by non-
target branch embolization by NBCA. In both cases, a 
low viscosity mixture of NBCA and iodized oil (i.e. ratio 
of NBCA to lipiodol 1:10) was used. Thus, from our lim-
ited experience we speculate that the appropriate viscos-
ity might be higher, for example, 1:2–1:3 ratios. Prior coil 
placement could decrease blood flow in the endoleak sac, 
which may help to prevent distal embolization by NBCA.
Our study has some limitations. The sample size was 
small and its design was retrospective and observational. 
Recurrence has been observed years after embolization. 
Our follow-up period was not long (mean, 6  months), 
and the timing of follow-up studies was irregular. Fur-
thermore, there remains a possibility that some of the 
aneurysms that increased in size for which embolization 
was performed might have stabilized without any ther-
apy. However, we believe that the high frequency of tech-
nical and clinical success and low rate of complications 
shown in the present study suggest the effectiveness and 
safety of embolization for T2EL.
In conclusion, embolization of T2ELs effectively arrests 
growth, as sacs stabilized in many patients with T2ELs 
after embolotherapy. We suggest embolization might be 
safe and effective treatment, a less invasive treatment 
option, as the first choice to address T2EL.
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